

Special Issue

Novel Anti-cancer Lead Compounds

Message from the Guest Editors


Currently, hundreds of different anticancer drugs are available on the market or are under development worldwide. However, there remains a need to screen for novel drugs utilizing innovative and combined mechanisms. This need is not merely a matter of overcoming drug resistance but also a means of fighting cancer through diverse approaches. Drugs designed for other purposes can demonstrate activity against cancer cells. Because cancer cells exhibit highly active metabolism, several pathways are active at the same time and must function in an integrated manner to guarantee cells' ability to survive and proliferate at extremely high rates. In this context, it is a great pleasure to invite you to contribute to this thematic Special Issue of *Molecules* on Novel Anti-Cancer Lead Compounds that will cover the latest research trends and applications in the field. Submissions of reviews and original research papers are highly welcome.

Guest Editors

Dr. Fernando de Carvalho da Silva
Prof. Dr. Vitor Francisco Ferreira
Dr. Luana Da Silva Magalhães Forezi

Deadline for manuscript submissions

closed (31 March 2023)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed




mdpi.com/si/101089

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 30th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarInLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the second half of 2025).